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analysisAbstract The paper emphasizes on the synthesis of Palladium(II) iodide complexes containing
based ligands. The new compounds of general formulae [Pd(L)4]I2 where L = Thiourea (Tu),
Methylthiourea (Metu), Dimethylthiourea (Dmtu), Tetramethylthiourea (Tmtu), Imidazolidine-2-
thione (Imt), Mercaptopyridine (Mpy), Mercaptopyrimidine (Mpm), and Thionicotinamide (Tna)
were prepared simply by reacting K2[PdCl4] with the corresponding thioamides in 1:2 M ratio
and then with 2 equivalents Potassium iodide. The complexes were characterized by elemental anal-
ysis and spectroscopic techniques (IR, 1H and13C NMR). All the synthesized complexes were
screened for antibacterial activity and some of compounds have shown good activities against both
gram positive and gram negative bacteria. POM analyses reveal that the compounds are only
slightly toxic and present a potential for antibacterial activity. Moreover, they have 16–23% drug
score which is an important parameter for the compound possessing the drug properties.
 2015 The Authors. Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
The coordination and structural chemistry of Palladium based
complexes with donor atoms, especially sulfur containing
ligands have been extensively studied.1–5 Palladium(II)
complexes with heterocyclic thiones and thioureas as ligands
280 S. Nadeem et al.showing a square-planar geometry have promising bio-relevant
activities, particularly Mercaptopyrimidine, 6-Mercaptopurines,
Imidazolidine-2-thione, and Diazinane-2-thione and their
complexes with Palladium(II) are known to have antitumor
activities.6–16 In view of great potential, several complexes of
thioamides with Au(I), Ag(I), Cu(I) Zn(II) Mo(II), Cd(II) Pd
(II) and Hg(II) have been widely studied.17–36
The treatment of infectious diseases still remains an impor-
tant and challenging problem because of a combination of fac-
tors including emerging infectious diseases and the increasing
number of multi-drug resistant microbial pathogens. In spite
of a large number of antibiotics and chemotherapeutics avail-
able for medical use, at the same time the emergence of old and
new antibiotic resistance created in the last decades revealed a
substantial medical need for new classes of antimicrobial
agents. There is a real perceived need for the discovery of
new compounds endowed with antimicrobial activity, possibly
acting through mechanism of action, which is distinct from
those of well-known classes of antimicrobial agents to which
many clinically relevant pathogens are now resistant. Due to
the outbreak of infectious diseases caused by different patho-
genic bacteria and the development of antibiotic resistance,
researchers are searching for new antibacterial agents.
In continuation of our interest to further study the struc-
tural chemistry and biological properties of Palladium–sulfur
interaction, in this paper, we describe the coordination of Pal-
ladium(II) iodide with a number of heterocyclic thiones as well
as thioureas and their characterization by IR, 1H and 13C
NMR spectroscopic techniques. Moreover, we have also inves-
tigated the antibacterial activities of these complexes. The
knowledge of coordination behavior of thioamides toward Pal-
ladium(II) would be useful to understand the interactions of
heavy metals to nucleotides and related compounds, which
may have antitumor activity. The structures of the ligands used
in this study are shown in Scheme 1.H2N
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2.1. Chemicals
Palladium(II) chloride was purchased from Degussa AG
40474, Dusseldorf, Germany. The ligands, Thiourea (Tu),
Methylthiourea (Metu), N,N0-Dimethylthiourea (Dmtu),
Tetramethylthiourea (Tmtu), 2-Mercaptopyridine (Mpy), 2-
Mercaptopyrimidine (Mpm), and Thionicotinamide (Tna)
were purchased from ACROS Organics, USA.
Imidazolidine-2-thione (Imt) was prepared according to the
published procedure.12
2.2. Synthesis of the complexes
Potassium tetrachloropalladate (II) was prepared as described
in the literature.20 Slight excess of two equivalents of Potas-
sium chloride 1:2.25 ratio was added into the solution of Pal-
ladium chloride in 25 cm3 of distilled water with stirring for
half an hour. The mixture was cooled in ice after few minutes
yellowish-brown crystals of Potassium tetrachloropalladate
(II) were formed which was separated by ﬁltration and recrys-
tallized from water containing few drops of HCl.
All the complexes were prepared by adding 2 equivalents of
thioamides already dissolved in 15 mL methanol solution of
K2[PdCl4] (0.326 g) in 15 mL of water (Scheme 2). After half
an hour stirring 2 equivalents of aqueous solution of Potas-
sium iodide were added and stirred the solutions for one hour.
On mixing dark brown or reddish color solutions were
obtained except for [Pd(Metu)4]I2 complex, where a shows a
pale yellow color solution was obtained. All these solutions
were ﬁltered and washed with methanol and were kept at room
temperature for three to ﬁve days. Solid products were
obtained from water–methanol mixture on slow evaporation.C
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Table 1 Proposed structure of the synthesized compounds.
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282 S. Nadeem et al.The experimental yield of the products was around
60–75%. The proposed structures of the complexes are
shown in Table 1. The elemental analysis and melting points
(MP) of the complexes are given in Table 2.
2.3. Measurements
Elemental analysis was carried out on a Leco CHNS-932
Leco Corporation USA. Melting point was recorded on
an Electrothermal IA 9000 Series, Essex SS2 5PH UK.
FT-IR spectra were recorded on a Thermo Nicolet Nexus
6700 USA. The 1H and 13C NMR spectra of the ligands
and their complexes in DMSO-d6 were obtained on Bruker
Avance 300 MHz NMR Spectrometer operating at frequen-
cies of 300.00 MHz and 75.47 MHz respectively at 300 K.
The spectral conditions were as follows: 32 K data points,
1.822 s acquisition time, 2.00 s pulse delay and 6.00 ls pulse
width. The 13C chemical shifts were measured relative to
TMS.
2.4. Antibacterial activities of the complexes
The antibacterial activity of all synthesized metal complexes
has been investigated against four bacteria, two G (+) bac-
terial strains i.e., Staphylococcus aureus ATCC 25923, and
Bacillus subtilis DSM 3256, and two G () bacterial strains
i.e., Escherichia coli ATCC 25922, and Pseudomonas
aeruginosa ATCC 10197 by the agar well diffusion method.
Imipenem was used as standard antibiotic which is
b-Lactam antibiotic effective against G (+ve) as well as
G (ve) bacteria. 3 mg of the test samples (ligands & com-
plexes) was dissolved in 1 mL of DMSO. 2–3 mL nutrient
broth (0.8 g/100 mL) was prepared in distilled water with
pH 7 and was autoclaved at 121 C, 15 psi pressure and
for 20 min. 24 h fresh culture grown on nutrient broth at
pH 7 was used for sensitivity testing. To compare the tur-
bidity of bacterial cultures McFarland BaSO4 solution
was used as turbidity standard. To perform antibacterial
assay, nutrient agar medium was prepared by dissolving
2 g/100 mL in distilled water with pH 7 and the medium
was autoclaved. The nutrient agar medium was poured in
Petri dishes and allowed to solidify. Using sterile cotton
swabs lawns of test cultures were prepared on labeled
plates. Four wells per plate were prepared with the help
of sterile cork borer (2 mm). Using micropipette, 30 lL of
test solution was poured in respective labeled wells. Now,
these experimental plates were incubated for 24 h and zones
of inhibition (%) were measured and compared with stan-
dard antibiotic imipenem having zone inhibition 21 mm,
18 mm, 16 mm and 18 mm, respectively.37,38
2.5. Petra/Osiris/Molinspiration (POM) analyses
Petra/Osiris/Molinspiration (POM) analysis is one of the
well-known approaches that has been used regularly to pro-
duce the two dimensional models to identify and to indicate
the type of pharmacophore site that affects biological
activity with a change in the chemical substitution. The
advantages of POM are the ability to predict the biological
activities of the molecules and to represent the relationships
between steric/electrostatic property and biological activity
Table 2 CHNS analysis, and MP of [Pd(L)4]I2 complexes.
Compound Color Found (calculated) % MP (C)
C H N S
[Pd(Tu)4]I2 Dark brown 7.20 (7.22) 2.23 (2.41) 16.31 (16.85) 9.57 (9.63) 248–249
[Pd(Metu)4]I2 Pale yellow 13.41 (13.32) 3.36 (3.33) 15.62 (15.54) 8.90 (8.88) 214–216
[Pd(Dmtu)4]I2 Dark brown 18.48 (18.53) 4.10 (4.12) 14.39 (14.42) 8.21 (8.24) 202–204
[Pd(Tmtu)4]I2 Dark brown 27.01 (26.98) 5.42 (5.40) 12.57 (12.59) 7.21 (7.19) 245–247
[Pd(Imt)4]I2 Dark brown 18.75 (18.73) 3.15 (3.12) 14.51 (14.57) 8.33 (8.32) 242–244
[Pd(Mpy)4]I2 Dark brown 29.86 (29.82) 2.51 (2.48) 6.94 (6.96) 7.91 (7.95) 199–202
[Pd(Mpm)4]I2 Dark red 23.71 (23.74) 2.00 (1.98) 13.87 (13.85) 7.89 (7.91) 253–255
[Pd(Tna)4]I2 Dark brown 31.58 (31.56) 2.68 (2.63) 12.31 (12.27) 7.04 (7.01) 193–195
Table 3 Selected IR absorption (cm1) for free ligands and their Palladium(II) iodide complexes.
Compound m(C‚S) m(NAH) m(NAH) m(CAN) m(PdAS) m(PdAI)
Tu 730 3156, 3365 1604 1473 – –
[Pd(Tu)4]I2 706 3176, 3379 1608 1384 327 270
Metu 634 3163, 3245 1624 1488 – –
[Pd(Metu)4]I2 762 3176 1619 1469 328 279
Dmtu 641 3203 1552 1521 – –
[Pd(Dmtu)4]I2 717 3283, 3340 1573 1492 324 260
Tmtu 622 – – 1491 – –
[Pd(Tmtu)4]I2 675 2923, 3468 1553 1493 335 279
Imt 510 3200 1499 1307 – –
[Pd(Imt)4]I2 562 3306 1507 1317 317 273
Mpy 613 3176 1578 1487 – –
[Pd(Mpy)4]I2 754 2917, 3064 1498 1573 304 269
Mpm 624 3053 1602 1491 – –
[Pd(Mpm)4]I2 748 3032 1525 1567 301 272
Tna 699 3180 1675 1455 – –
[Pd(Tna)4]I2 671 3136, 3278 1613 1464 304 265
Table 4 1H NMR data of the ligands and their Palladium(II) iodide complexes.a
Compound NH2 NH H-2 H-3 H-4 H-5 H-6 NACH3
Tu 7.06, s – – – – – – –
[Pd(Tu)4]I2 7.88, s – – – – – – –
Metu 7.45, s 7.60, s – – – – – 2.80, s
[Pd(Metu)4]I2 8.63, s 7.65, s – – – – – 2.82, s
Dmtu – 7.38, s – – – – – 2.81, s
[Pd(Dmtu)4]I2 – 8.51, s – – – – – 2.84,
2.90, s
Tmtu – – – – – – – 3.08, s
[Pd(Tmtu)4]I2 – – – – – – – 3.11, s
Imt – 7.99, s 3.62, d – – – – –
[Pd(Imt)4]I2 – 8.96, s 3.90, d – – – – –
Mpy – 10.12, s 7.53, d 7.40, d 7.90, t 7.23, d – –
[Pd(Mpy)4]I2 – 10.21, s 7.57, d 7.45, d 7.99, t 7.25, d – –
Mpm – 8.28, t 8.30, d – 8.20, d – – –
[Pd(Mpm)4]I2 – 8.97, t 8.36, d – 8.24, d – – –
Tna 9.12, s 10.12, s – 7.90, t 7.60, t 8.23, d 7.16, s –
[Pd(Tna)4]I2 9.16, s 10.21, s – 7.95, t 7.69, t 8.25, d 7.20, s –
a Numbering is in accordance with Scheme 1.
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Table 5 13C NMR data of the ligands and their Palladium(II)
iodide complexes. a
Compound C-1 C-2 C-3 C-4 C-5 C-6
Tu 183.8 – – – – –
[Pd(Tu)4]I2 178.06 – – – – –
Metu 181.3 31.1 – – – –
[Pd(Metu)4]I2 175.5 32.4 – – – –
Dmtu 183.0 30.7 – – – –
[Pd(Dmtu)4]I2 174.9 31.03 – – – –
Tmtu 193.4 42.1 – – – –
[Pd(Tmtu)4]I2 187.1 44.7 – – – –
Imt 183.9 44.0 – – – –
[Pd(Imt)4]I2 178.4 45.4 – – – –
Mpy 177.7 133.2 113.9 137.5 137.9 –
[Pd(Mpy)4]I2 167.57 132.3 120.0 139.4 140.3 –
Mpm 181.9 155.0 154.8 110.0 – –
[Pd(Mpm)4]I2 172.9 159.3 158.2 116.4 – –
Tna 198.0 135.0 135.3 123.1 147.6 151.6
[Pd(Tna)4]I2 194.9 136.4 137.6 126.2 141.8 148.0
a Numbering is in accordance to the Scheme 1.
284 S. Nadeem et al.in the form of pharmacophore site, which gives key features on
not only the ligand–receptor interaction, but also on the topol-
ogy of the receptor.393. Results and discussion
3.1. Elemental analysis (CHN)
Elemental analysis data are given in Table 2. It can be seen
that the observed values are in very good agreement with the
calculated values that show the purity of the synthesized
compounds.Table 6 Antibacterial activity of the ligands and their Palladium(II
(% Zone of inhibition of Std. Drugs, Ligands and Complexes)
Compound Staphylococcus aureus Bacillus sub
% value % value
Imipenem 100 (21 mm) 100 (18 mm
Tu 0 0
[Pd(Tu)4]I2 43 45
Metu 0 17
[Pd(Metu)4]I2 14 17
Dmtu 10 11
[Pd(Dmtu)4]I2 0 0
Tmtu 0 11
[Pd(Tmtu)4]I2 10 17
Imt 0 22
[Pd(Imt)4]I2 14 22
Mpy 52 95
[Pd(Mpy)4]I2 14 39
Mpm 19 45
[Pd(Mpm)4]I2 48 56
Tna 0 0
[Pd(Tna)4]I2 33 03.2. IR studies
Selected IR spectroscopic vibrational bands for the free ligands
and their Palladium(II) complexes are given in Table 3. Low
frequency shifts in the m(C‚S) band at 506–739 cm1, m
(NAH) band at 1487–1675 cm1, m(CAN) band at 1307–
1602 cm1 and high frequency shifts in m(NAH) band at
3023–3379 cm1 shifted to 562–762 cm1, 1498–1619 cm1,
1317–1573 cm1 and 2917–3468 cm1 respectively in the com-
plexes were observed indicating coordination through sulfur
compared with free ligands. The peaks at 301–335 cm1 and
260–279 cm1 were attributed to the m(PdAS) and m(PdAI)
vibrations, respectively.19,40,41
3.3. NMR studies
The 1H NMR data of the ligands and their complexes are
given in Table 4. In 1H NMR spectra of the complexes, the
NAH signal of thiones becomes less intense upon coordination
and shifted downﬁeld by 0.03–1.74 ppm from their positions in
free ligands. The downﬁeld shifting of the NAH proton is
related to an increase of the p electron density in the CAN
bond upon complexation.22 The appearance of NAH signal
shows that the ligands are coordinated to Palladium(II) via
the thioamide group. The NAH protons of Dmtu are equiva-
lent but after coordination they become nonequivalent as NH2
appears as triplets in Dmtu.
The 13C NMR chemical shifts for the ligands and [Pd(L)4]I2
complexes are given in Table 5. Upﬁeld shifts are observed in
the C‚S resonance of ligands upon its complexation with
Palladium(II). The upﬁeld is attributed to the lowering of
C‚S bond order and shifting of N? C electron density pro-
ducing a partial double bond character in the CAN bond, as
observed in the other metal complexes of thiourea.14,19,20,36
In all complexes the C-2 resonance appears upﬁeld by 2.97–
10.12 ppm compared with the free ligands. Among these) iodide complexes.
tilis Escherichia coli Pseudomonas aeruginosa
% value % value
) 100 (16 mm) 100 (18 mm)
13 0
57 17
45 33
13 33
13 11
6 0
0 0
13 22
38 28
0 17
100 83
44 50
63 45
69 67
19 0
0 0
Table 7 Osiris calculations of toxicity risks and drug-score of the selected compounds.
Compound # Toxicity risks Bioavailability and drug-score
Mutagenic Tumorigenic Irritant Reproductive eﬀective cLogP Solubility TPSA Druglikeness Drug-score
[Pd(Dmtu)4]I2 ++ ++ ++ ++ 1.05 1.97 52.04 2.72 0.18
[Pd(Imt)4]I2 ++ ++ ++ ++ 1.05 1.97 52.04 2.72 0.18
[Pd(Metu)4]I2 ++ ++ ++ ++ 0.35 1.08 24.06 0.87 0.21
[Pd(Mpy)4]I2 ++ ++ ++ ++ 0.18 1.08 6.48 4.23 0.16
[Pd(Mpm)4]I2 ++ ++ ++ ++ 0.32 1.95 24.06 0.20 0.23
[Pd(Tmtu)4]I2 ++ ++ ++ ++ 0.28 3.13 12.03 1.06 0.19
[Pd(Tu)4]I2 ++ ++ ++ ++ 0.13 2.72 24.39 0.83 0.20
[Pd(Tna)4]I2 ++ ++ ++ ++ 0.31 1.93 38.91 1.36 0.18
Imipenem + + + + 1.16 0.97 139.0 5.28 0.95
+= not toxic; ++= slightly toxic.
Table 8 Molinspiration property and Molinspiration bioactivity score data of the selected compounds and reference drugs.
Data Pd(Dmtu)4]I2 Pd(Imt)4]I2 Pd(Metu)4]I2 Pd(Mpy)4]I2 Pd(Mpm)4]I2 Pd(Tmtu)4]I2 Pd(Tu)4]I2 Pd(Tna)4]I2 Imipenem
miLogP 1.65 0.019 0.901 4.208 2.361 1.65 0.152 2.073 0.734
TPSA 48.108 48.108 76.1 31.582 57.366 48.108 104.092 77.83 113.715
natoms 15.0 15.0 13.0 17.0 17.0 15 11 21.0 20.0
MW 568.584 564.552 540.53 582.566 584.542 568.584 512.476 636.618 299.352
nON 4 4 4 2 4 4 4 4 7
nOHNH 4 4 6 2 2 4 8 4 4
Nviolations 1 1 2 1 1 1 2 1 0
Nrotb 4 0 2 0 0 4 0 2 7
Volume 279.297 258.576 243.947 276.231 267.919 279.297 208.597 320.25 255.433
GPCR L 0.63 0.47 1.00 0.26 0.35 0.63 1.20 0.01 0.32
ICM 0.25 0.19 0.51 0.07 0.13 0.25 0.57 0.08 0.21
KI 0.55 0.62 0.72 0.20 0.34 0.55 1.01 0.04 0.56
NRL 0.81 0.86 1.34 0.38 0.53 0.81 0.45 0.21 0.21
PI 0.70 0.66 0.81 0.46 0.55 0.70 1.01 0.18 0.97
EI 0.27 0.23 0.36 0.08 0.12 0.27 0.50 0.04 1.00
GPCR L= GPCR ligand, ICM= ion channel modulator, KI = kinase inhibitor, NRL= nuclear receptor ligand, PI = protease inhibitor,
EI = enzyme inhibitor.
New Palladium(II) iodide complexes with thioamides 285complexes the Mpy complexes are the most stable complex due
to its most and signiﬁcant shift in the C-2 resonance.
3.4. Antibacterial studies
Metal complexes with thioamides are capable of inhibiting
bacterial growth and activity by interfering with the metabolic
process in the bacteria.1–3,14,20,33,36,38,41,42 In the present work,
we have synthesized thioamides Palladium(II) iodide com-
plexes and their. Antibacterial activities have been determined
against four strains of bacteria S. aureus (ATCC 25923), B.
subtilis (DSM 3256), E. coli (ATCC 25922), and P. aeruginosa
(ATCC 10197). The results are shown in Table 6. Better
antibacterial activities were observed as compared to a stan-
dard drug. The Palladium(II) complexes containing thiourea,
mercaptopyridine and mercaptopyrimidine exhibited good
activity against all bacteria S. aureus, B. subtilis, E. coli and
P. aeruginosa. The complexes of methylthioure, a tetram-
ethylthiourea and imidazolidine-2-thione exhibited relatively
low activity against all of these bacteria. The complexes of
dimethylthiourea and thionicotinamide are ineffective against
all bacteria i.e. all bacteria show resistance against these two
complexes. The antibacterial activity of complexes may beattributed to their inhibition in the metabolic pathway which
alter the replication of DNA. Moreover the Palladium(II)
complexes have the ability to form hydrogen bonding with
the constituents of cell and cell wall43 or direct interaction with
membrane, enzyme and proteins. The ligands have the capabil-
ity to carry metal to the target (DNA) and allow it to interact
with it. Weak coordinated ligands may be the best carrier for
metal ions to the biological systems. The inactivity or
decreased biological activity of some of the complexes may
be related to the strongly coordinated ligands with the metal
ions.44,45 It has been observed that antibacterial activity
decreases on complexation, while some ligands are biologically
inactive but upon coordination showed biological activity. The
complexes which exhibit signiﬁcant biological activity show
their potential to be used as antibacterial agents.
3.5. Petra/Osiris/Molinspiration (POM) analyses
Petra/Osiris/Molinspiration (POM) analyses were performed
to investigate the potential pharmacophore sites of the synthe-
sized compounds and reference drug (imipenem).
Modern drug discovery is based in large part on high
throughput screening of small molecules against macromolec-
286 S. Nadeem et al.ular disease targets requiring that molecular screening libraries
contain drug-like or lead-like compounds. We have analyzed
the known standard references (SR) for drug-like properties.
With this information in hand, we have established a strategy
to design speciﬁc drug-like compounds.
3.5.1. Petra analysis
On the basis of the new ﬁnding, we can conclude that the
synthesized compounds have the C‚S, ANH2, NH and
AN(CH3)2 moieties which possess a potential for antibacterial/
antifungal activities. For antiviral/antifungal activity, the
compound possesses (Xd—Yd+) pharmacophore site and also
it was hypothesized that the difference in charge between
X and Y of the same dipolar pharmacophoric site should
facilitate the inhibition of bacteria more than viruses.46
3.5.2. Osiris calculations
Remarkably well behaved mutagenicity of divers synthetic
molecules classiﬁed in database of Celeron Company of Swiss
can be used to quantify the role played by various organic
groups in promoting or interfering with the way a drug can
associate with DNA. The Osiris calculations are tabulated in
Table 7. Toxicity risks (mutagenicity, tumorigenicity, irrita-
tion, and reproduction) and physicochemical properties
(cLogP, solubility, drug-likeness and drug-score) of com-
pounds were calculated by the methodology developed by
Osiris. The toxicity risk predictor locates fragments within a
molecule, which indicate a potential toxicity risk. Toxicity risk
alerts are an indication that the drawn structure may be harm-
ful concerning the risk category speciﬁed. From the data eval-
uated in Table 7 it is observed that all the complexes are
supposed to be slightly mutagenic, tumorigenic, irritant with
slight reproductive effects when run through the mutagenicity
assessment system in comparison with the standard/reference
drugs. The reference drug (imipenem) is non-mutagenic, non-
tumorigenic, non-irritant with no reproductive effect as shown
in Table 7. Low hydrophilicities and low cLogP values may
cause good absorption or permeation. It has been shown that
for compounds to have a reasonable probability of good
absorption, their cLogP value must not be greater than 5.0.
On this basis, all the compounds possessed cLogP values are
quite less than 5. The aqueous solubility of a compound signif-
icantly affects its absorption and distribution characteristics.
Typically, a low solubility goes along with a bad absorption
and therefore the general aim is to avoid poorly soluble com-
pounds. Our estimated Solubility (S) value is a unit stripped
logarithm (base 10) of a compound’s solubility in mol/L. There
are more than 80% of the drugs on the market having an (esti-
mated) S value greater than 4.47–49 In our case the S values
for studied compounds are in the range of 1.08 and 3.13.
Further, Table 7 shows drug likeness of the compounds which
are almost in the comparable zone with that of standard drug
used for comparison. The compounds also possess the drug-
score though smaller than that of the reference drug.
3.5.3. Molinspiration calculations
cLogP (octanol/water partition coefﬁcient) is calculated by the
methodology developed by Molinspiration as a sum of
fragment-based contributions and correction factors (Table 8).
The method is very stout and is able to process practically all
organic and most organometallic molecules. Molecular PolarSurface Area (TPSA) is calculated as a sum of fragment con-
tributions. S-, N-, I and Pd centered polar fragments are con-
sidered. PSA has been shown to be a very good descriptor
characterizing drug absorption, including intestinal absorp-
tion, bioavailability, Caco-2 permeability and blood–brain
barrier penetration. Prediction results of the studied com-
pounds (molecular properties (TPSA and GPCR ligand)) are
valued (Table 8). Lipophilicity (cLogP value) and polar sur-
face area (TPSA) values are two important properties for the
prediction of per oral bioavailability of drug molecules.47–49
Therefore cLogP and TPSA values for compounds were calcu-
lated using molinspiration software programs and compared
with the values obtained for standard drugs imipenem (for
antibacterial activity). The calculated cLogP values for the
investigated compounds are in the range of 0.13 to 0.31
which are in the acceptable range. So these compounds are
expected to present good bioavailability.47–49
The polar surface area (TPSA) is calculated from the sur-
face areas that are occupied by oxygen and nitrogen atoms
and by hydrogen atoms attached to them and/or metal atom.
Thus, the TPSA is closely related to the hydrogen bonding
potential of a compound. Molecules with TPSA values
around of 160 or more are expected to exhibit poor intestinal
absorption. It is to be noted that cLogP and TPSA values
are the two important parameters, although not sufﬁcient cri-
teria for predicting oral absorption of a drug. All the com-
pounds (except Pd(Metu)4]I2 and Pd(Tu)4]I2) have one
violation from the Rule of 5. Two or more violations of
the Rule of 5 suggest the probability of problems in bioavail-
ability of the standard drug.48,49 Properties such as
hydrophobicity, electronic distribution, hydrogen bonding
characteristics, molecule size, ﬂexibility and presence of vari-
ous pharmacophores features inﬂuence the behavior of mole-
cule in a living organism, including bioavailability, transport
properties, afﬁnity to proteins, reactivity, toxicity, metabolic
stability and many others. Activity of the synthesized com-
pounds and standard drug was rigorously analyzed under
four criteria of known successful drug activity in the areas
of GPCR ligand activity, ion channel modulation, Kinase
inhibition activity, and nuclear receptor ligand activity.
Results are shown in Table 8 by means of numerical assign-
ment. Thus, these compounds are expected to have near sim-
ilar activity to the standard drug used based upon these four
rigorous criteria (GPCR ligand, ion channel modulator,
Kinase inhibitor and nuclear receptor ligand).47–494. Conclusion
The present study shows that the thioamide ligands coordinate
with Palladium(II) iodide in the thione form in solution as well
as in the solid state. All ligands behave as S-donors and are
binding in a terminal mode and no bridging of groups between
metal centers is found. The complexation was conﬁrmed by the
downﬁeld shift of the NAH proton as a result of increase of p
electron density in the CAN bond. In the 13C NMR spectra of
the complexes upﬁeld shifts in the C‚S resonance also sup-
port the binding of ligands to Palladium(II). The shift differ-
ence of the C‚S resonance may be related to the strength
of metal-sulfur bond. Some of the screened compounds have
shown good antibacterial activity which has potential for their
use in future as antibacterial agents.
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